12 Month Timeline - How Cannabis Rescheduling Actually Takes Effect
Announcement
President signals intent or issues executive direction
DEA Rulemaking
DEA drafts proposed rule; public notice and comment period
Final DEA Rule
DEA reviews comments and issues final scheduling decision
Federal Register Publication
Legal effective date (often immediate or 30-60 days later)
No Federal Register publication = no change in law
Read More
A data-backed analysis of Sugar Defender, including updated metabolic research, verified user trends, ingredient science, complaint patterns, safety findings, clinical plausibility, and whether this popular blood sugar supplement truly works in 2025.
Read More
A medically guided 2025 investigation into Prostadine's iodine complex, prostate detox claims, urinary-flow results, side effect reports, and what recent consumer data reveals about this trending formula.
Read MoreDriven by rollout of the next-generation Wattbike AIR-PRO across Germany's Fitness First's premium Black Label facilities
Major order follows April's $1M+ order from Woodway for the US market
Read More
More top doctors joined the region's leading physician-owned healthcare group in 2025, increasing patients' access to primary care and medical specialties including family medicine, cardiology, vascular surgery, pain management, rheumatology, and podiatry.
Read MoreConditional approval extended through December 2026 for the treatment of CID in dogs
CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected
100% of patients in Cohorts 1-3 remain free of cytokine release syndrome
CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care
Read MoreJaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID
Company completed meeting with FDA October 2, 2025 for advice on advancing its ongoing placebo-controlled trial of crofelemer in support of possible expedited approval pathway for crofelemer for treatment of MVID
Read MoreLaunch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price
Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors
Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience
Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have access to controlled substances for legitimate medical use.
Today, the evidence shows the opposite: DEA officials laundering cartel money, DEA lawyers defending unconstitutional judicial processes, DEA executives cycling into industry roles they once regulated and DEA policies obstructing legitimate FDA authorized medical research.
Read More
"Queer Safety: Building Truly Affirming Systems for LGBTQ+ and Neurodivergent Lives"
A Candid Conversation on Safety, Ethics, and Affirming Care for LGBTQ+ and Neurodivergent Communities
Read More
MMJ International Holdings Exposes the Impossible Federal Catch-22 Blocking FDA Regulated Cannabis Medicine. "This is an equation with no solution. To follow the rule is to commit a felony, and to follow the law is to violate the rule. This is the first paradox I've encountered that violates logic and the U.S. criminal code simultaneously." stated Duane Boise, CEO MMJ International Holdings.
Read More
